Literature DB >> 19594633

CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions.

Lars Nitschke1.   

Abstract

Siglecs (sialic acid-binding immunoglobulin-like lectins) are sialic acid-binding proteins, which are expressed on many cell types of the immune system. B cells express two members of the Siglec family, CD22 (Siglec-2) and Siglec-G, both of which have been shown to inhibit B-cell signaling. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. Interaction with these ligands in cis regulates the association of CD22 with the BCR and thereby modulates the inhibitory function of CD22. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. Siglec-G is a recently identified protein with an inhibitory function restricted to a B-cell subset, the B1 cells. Siglec-G inhibits Ca2+ signaling specifically in these cells. In addition, it controls the cellular expansion and antibody secretion of B1 cells. Thus, both Siglecs modulate BCR signaling on different B-cell populations in a mutually exclusive fashion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19594633     DOI: 10.1111/j.1600-065X.2009.00801.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  52 in total

Review 1.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

Review 2.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

Review 3.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 4.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

Review 5.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

6.  Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo.

Authors:  Anne Baerenwaldt; Anja Lux; Heike Danzer; Bernd M Spriewald; Evelyn Ullrich; Gordon Heidkamp; Diana Dudziak; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

7.  O-Acetylation of sialic acid on Group B Streptococcus inhibits neutrophil suppression and virulence.

Authors:  Shannon Weiman; Satoshi Uchiyama; Feng-Ying C Lin; Donald Chaffin; Ajit Varki; Victor Nizet; Amanda L Lewis
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

8.  STALing B cell responses with CD22.

Authors:  Craig P Chappell; Edward A Clark
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

9.  Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22.

Authors:  Fabian Pfrengle; Matthew S Macauley; Norihito Kawasaki; James C Paulson
Journal:  J Immunol       Date:  2013-07-08       Impact factor: 5.422

Review 10.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.